Hepatocellular carcinoma: Novel therapeutic approaches;Hepatozelluläres karzinom: Innovative therapieansätze

Praxis

Volumn 96, Issue 14, 2007, Pages 553-562

  Mohr, L ^a  

^a Ortenau Klinikum   (Germany)

Author keywords

Anti angiogenesis; Hepatocellular carcinoma; Immunotherapy; Signal transduction; Targeted therapy

Indexed keywords

EID: 34247521508     PISSN: 16618157     EISSN: 16618165     Source Type: Journal    
DOI: 10.1024/1661-8157.96.14.553     Document Type: Review

References (45)

1. Bosch F.X., Ribes J., Diaz M., Cleries R.: Primary liver cancer: worldwide incidence and trends. Gastroenterology 127: 5-16, 2004.
2. Song T.J., Ip E.W., Fong Y.: Hepatocellular carcinoma: current surgical management. Gastroenterology 127: 248-260, 2004.
3. Mazzaferro V., Regalia E., Doci R., Andreola S., Pulvirenti A., Bozzetti F., Montalto F., Ammatuna M., Morabito A., Gennari L.: Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med 334: 693-699, 1996. (Pubitemid 26079803)
4. Huang G.T., Lee P.H., Tsang Y.M., Lai M.Y., Yang P.M., Hu R.H., Chen P.J., Kao J.H., Sheu J.C., Lee C.Z., Chen D.S.: Percutaneous ethanol injection versus surgical resection for the treatment of small hepatocellular carcinoma: a prospective study. Ann Surg 242: 36-42, 2005.
5. Lin S.M., Lin C.J., Lin C.C., Hsu C.W., Chen Y.C.: Radiofrequency ablation improves prognosis compared with ethanol injection for hepatocellular carcinoma < or = 4 cm. Gastroenterology 127: 1714-1723, 2004.
6. Llovet J.M., Bruix J.: Systematic review of randomized trials for unresectable hepatocellular carcinoma: Chemoembolization improves survival. Hepatology 37: 429-442, 2003. (Pubitemid 36152543)
7. Yeo W., Mok T.S., Zee B., Leung T.W., Lai P.B., Lau W.Y., Koh J., Mo F.K., Yu S.C., Chan A.T., Hui P., Ma B., Lam K.C., Ho W.M., Wong H.T., Tang A., Johnson P.J.: A randomized phase III study of doxorubicin versus cisplatin/interferon alpha-2b/ doxorubicin/fluorouracil (PIAF) combination chemotherapy for unresectable hepatocellular carcinoma. J Natl Cancer Inst 97: 1532-1538, 2005. (Pubitemid 41631953)
8. Barbare J.C., Bouche O., Bonnetain F., Raoul J.L., Rougier P., Abergel A., Boige V., Denis B., Blanchi A., Pariente A., Milan C., Bedenne L.: Randomized controlled trial of tamoxifen in advanced hepatocellular carcinoma. J Clin Oncol 23: 4338-4346, 2005. (Pubitemid 46207007)
9. Yuen M.F., Poon R.T., Lai C.L., Fan S.T., Lo C.M., Wong K.W., Wong W.M., Wong B.C.: A randomized placebo-controlled study of long-acting octreotide for the treatment of advanced hepatocellular carcinoma. Hepatology 36: 687-691, 2002. (Pubitemid 34977180)
10. Thomas M.B., Abbruzzese J.L.: Opportunities for targeted therapies in hepatocellular carcinoma. J Clin Oncol 23: 8093-8108, 2005. (Pubitemid 46657412)
11. Hopfner M., Sutter A.P., Huether A., Schuppan D., Zeitz M., Scherubl H.: Targeting the epidermal growth factor receptor by gefitinib for treatment of hepatocellular carcinoma. J Hepatol 41: 1008-1016, 2004. (Pubitemid 39575669)
12. Philip P.A., Mahoney M.R., Allmer C., Thomas J., Pitot H.C., Kim G., Donehower R.C., Fitch T., Picus J., Erlichman C.: Phase II study of Erlotinib (OSI-774) in patients with advanced hepatocellular cancer. J Clin Oncol 23: 6657-6663, 2005. (Pubitemid 46190260)
13. Schwartz J.D.: Bevacizumab in hepatocellular carcinoma (HCC) in patients without metastasis and without invasion of the portal vein. ASCO-abstract 4122, 2005.
14. Strumberg D., Richly H., Hilger R.A., Schleucher N., Korfee S., Tewes M., Faghih M., Brendel E., Voliotis D., Haase C.G., Schwartz B., Awada A., Voigtmann R., Scheulen M.E., Seeber S.: Phase I clinical and pharmacokinetic study of the Novel Raf kinase and vascular endothelial growth factor receptor inhibitor BAY 43-9006 in patients with advanced refractory solid tumors. J Clin Oncol 23: 965-972, 2005. (Pubitemid 46202316)
15. Shah M.A..: Mature results of a phase I study of irinotecan and flavopirol: A clinically and biologically active regimen. ASCO-abstract 1051, 2003.
16. Mohr L., Geissler M., Blum H.E.: Gene therapy for malignant liver disease. Expert Opin Biol Ther 2: 163-175, 2002. (Pubitemid 34464819)
17. Yoon S.-K., Armentano D., Wands J.R., Mohr L.: Adenovirus-mediated gene transfer to orthotopic hepatocellular carcinomas in athymic nude mice. Cancer Gene Ther 8: 573-579, 2001. (Pubitemid 32786560)
18. Mohr L., Schauer J.I., Boutin R.H., Moradpour D., Wands J.R.: Targeted gene transfer to hepatocellular carcinoma cells in vitro using a novel monoclonal antibody-based gene delivery system. Hepatology 29: 82-89, 1999. (Pubitemid 29023990)
19. Yoon S.K., Mohr L., O'Riordan C.R., Lachapelle A., Armentano D., Wands J.R.: Targeting a recombinant adenovirus vector to HCC cells using a bifunctional Fab-antibody conjugate. Biochem Biophys Res Commun 272: 497-504, 2000. (Pubitemid 30444646)
20. Cao G., Kuriyama S., Gao J., Nakatani T., Chen Q., Yoshiji H., Zhao L., Kojima H., Dong Y., Fukui H., Hou J.: Gene therapy for hepatocellular carcinoma based on tumour-selective suicide gene expression using the alpha-fetoprotein (AFP) enhancer and a housekeeping gene promoter. Eur J Cancer 37: 140-147, 2001.
21. Kanai F., Lan K.H., Shiratori Y., Tanaka T., Ohashi M., Okudaira T., Yoshida Y., Wakimoto H., Hamada H., Nakabayashi H., Tamaoki T., Omata M.: In vivo gene therapy for alpha-fetoprotein-producing hepatocellular carcinoma by adenovirus-mediated transfer of cytosine deaminase gene. Cancer Res 57: 461-465, 1997. (Pubitemid 27081664)
22. Xu G.W., Sun Z.T., Forrester K., Wang X.W., Coursen J., Harris C.C.: Tissue-specific growth suppression and chemosensitivity promotion in human hepatocellular carcinoma cells by retroviral-mediated transfer of the wild-type p53 gene. Hepatology 24: 1264-1268, 1996. (Pubitemid 26365936)
23. Zender L., Kuhnel F., Kock R., Manns M., Kubicka S.: VP22-mediated intercellular transport of p53 in hepatoma cells in vitro and in vivo. Cancer Gene Ther 9: 489-496, 2002. (Pubitemid 34569031)
24. .Kaneko S., Hallenbeck P., Kotani T., Nakabayashi H., McGarrity G., Tamaoki T., Anderson W.F., Chiang Y.L.: Adenovirus-mediated gene therapy of hepatocellular carcinoma using cancer-specific gene expression. Cancer Res 55: 5283-5287, 1995.
25. Mohr L., Rainov N.G., Mohr U.G., Wands J.R.: Rabbit cytochrome P450 4B1: A novel prodrug activating gene for pharmacogene therapy of hepatocellular carcinoma. Cancer Gene Ther 7: 1008-1014, 2000. (Pubitemid 30483480)
26. Mohr L., Shankara S., Yoon S.K., Krohne T.U., Geissler M., Roberts B., Blum H.E., Wands J.R.: Gene therapy of hepatocellular carcinoma in vitro and in vivo in nude mice by adenoviral transfer of the Escherichia coli purine nucleoside phosphorylase gene. Hepatology 31: 606-614, 2000. (Pubitemid 30118628)
27. Krohne T.U., Shankara S., Geissler M., Roberts B.L., Wands J.R., Blum H.E., Mohr L.: Mechanisms of cell death induced by suicide genes encoding purine nucleoside phosphorylase and thymidine kinase in human hepatocellular carcinoma cells in vitro. Hepatology 34: 511-518, 2001. (Pubitemid 32786641)
28. Wybranietz W.A., Gross C.D., Phelan A., O'Hare P., Spiegel M., Graepler F., Bitzer M., Stahler P., Gregor M., Lauer U.M.: Enhanced suicide gene effect by adenoviral transduction of a VP22-cytosine deaminase (CD) fusion gene. Gene Ther 8: 1654-1664, 2001. (Pubitemid 33085587)
29. Bitzer M., Lauer U.M.: Oncolytic viruses for genetic therapy of gastrointestinal tumors. Z Gastroenterol 7: 667-674, 2003. (Pubitemid 36916972)
30. Bischoff J.R., Kirn D.H., Williams A., Heise C., Horn S., Muna M., Ng L., Nye J. A., Sampson-Johannes A., Fattaey A., McCormick F.: An adenovirus mutant that replicates selectively in p53-deficient human tumor cells. Science 274: 373-376, 1996. (Pubitemid 26353341)
31. Habib N.A., Sarraf C.E., Mitry R.R., Havlik R., Nicholls J., Kelly M., Vernon C.C., Gueret-Wardle D., El-Masry R., Salama H., Ahmed R., Michail N., Edward E., Jensen S.L.: E1B-deleted adenovirus (dl1520) gene therapy for patients with primary and secondary liver tumors. Hum Gene Ther 12: 219-226, 2001. (Pubitemid 32163894)
32. Hallenbeck P.L., Chang Y.N., Hay C., Golightly D., Stewart D., Lin J., Phipps S., Chiang Y.L.: A novel tumor-specific replication-restricted adenoviral vector for gene therapy of hepatocellular carcinoma.Hum Gene Ther 10: 1721-1733, 1999. (Pubitemid 29328216)
33. Pawlik T.M., Nakamura H., Yoon S.S., Mullen J.T., Chandrasekhar S., Chiocca E.A., Tanabe K.K.: Oncolysis of diffuse hepatocellular carcinoma by intravascular administration of a replication-competent, genetically engineered herpesvirus. Cancer Res 60: 2790-2795, 2000. (Pubitemid 30395793)
34. Liu B.L., Robinson M., Han Z.Q., Branston R.H., English C., Reay P., McGrath Y., Thomas S.K., Thornton M., Bullock P., Love C.A., Coffin R.S.: ICP34.5 deleted herpes simplex virus with enhanced oncolytic, immune stimulating, and anti-tumour properties. Gene Ther 10: 292-303, 2003. (Pubitemid 36305598)
35. Wada Y., Nakashima O., Kutami R., Yamamoto O., Kojiro M.: Clinicopathological study on hepatocellular carcinoma with lymphocytic infiltration. Hepatology 27: 407-414, 1998. (Pubitemid 28081054)
36. Butterfield L.H.: Immunotherapeutic strategies for hepatocellular carcinoma. Gastroenterology 127: 232-241, 2004.
37. Grimm C.F., Ortmann D., Mohr L., Michalak S., Krohne T.U., Meckel S., Eisele S., Encke J., Blum H.E., Geissler M.: Mouse alpha-fetoprotein-specific DNA-based immunotherapy of hepatocellular carcinoma leads to tumor regression in mice. Gastroenterology 119: 1104-1112, 2000.
38. Vollmer C.M. Jr., Eilber F.C., Butterfield L.H., Ribas A., Dissette V.B., Koh A., Montejo L.D., Lee M.C., Andrews K.J., McBride W.H., Glaspy J.A., Economou J.S.: Alpha-fetoprotein-specific genetic immunotherapy for hepatocellular carcinoma. Cancer Res 59: 3064-3067, 1999. (Pubitemid 29316002)
39. Butterfield L.H., Meng W.S., Koh A., Vollmer C.M., Ribas A., Dissette V.B., Faull K., Glaspy J.A., McBride W.H., Economou J.S.: T cell responses to HLA-A*0201-restricted peptides derived from human alpha fetoprotein. J Immunol 166: 5300-5308, 2001. (Pubitemid 32280749)
40. .Geissler M., Mohr L., Köhler G., Grimm C.F., Krohne T.U., von Weizsacker F., Blum H.E.: Immunotherapy directed against alpha-fetoprotein results in autoimmune liver disease during liver regeneration in mice. Gastroenterology 121: 931-939, 2001. (Pubitemid 32959402)
41. Iwashita Y., Tahara K., Goto S., Sasaki A., Kai S., Seike M., Chen C.L., Kawano K., Kitano S.: A phase I study of autologous dendritic cell-based immunotherapy for patients with unresectable primary liver cancer. Cancer Immunol Immunother 52: 155-161, 2003. (Pubitemid 36384715)
42. Huang H., Chen S.H., Kosai K., Finegold M.J., Woo S.L.: Gene therapy for hepatocellular carcinoma: long-term remission of primary and metastatic tumors in mice by interleukin-2 gene therapy in vivo. Gene Ther 3: 980-987, 1996. (Pubitemid 26397472)
43. Sangro B., Mazzolini G., Ruiz J., Herraiz M., Quiroga J., Herrero I., Benito A., Larrache J., Pueyo J., Subtil J.C., Olague C., Sola J., Sadaba B., Lacasa C., Melero I., Qian C., Prieto J.: Phase I trial of intratumoral injection of an adenovirus encoding interleukin-12 for advanced digestive tumors. J Clin Oncol 22: 1389-1397, 2004. (Pubitemid 41103620)
44. Kuang M., Peng B.G., Lu M.D., Liang L.J., Huang J.F., He Q., Hua Y.P., Totsuka S., Liu S.Q., Leong K.W., Ohno T.: Phase II randomized trial of autologous formalin-fixed tumor vaccine for postsurgical recurrence of hepatocellular carcinoma. Clin Cancer Res 10: 1574-1579, 2004. (Pubitemid 38435545)
45. Takayama T., Sekine T., Makuuchi M., Yamasaki S., Kosuge T., Yamamoto J., Shimada K., Sakamoto M., Hirohashi S., Ohashi Y., Kakizoe T.: Adoptive immunotherapy to lower postsurgical recurrence rates of hepatocellular carcinoma: a randomised trial. Lancet 356: 802-807, 2000.